



**Prior Authorization Approval Criteria**  
*Department of Pharmacy Services*

**Generic Name:** lanthanum

**Brand Name:** Fosrenol

**Medication Class:** Phosphate removing agent

**FDA Approved Uses:** to reduce serum phosphate in patients with end-stage renal disease.

**Usual Dose:** Initial dose of 750mg -1500 mg a day. Most patients require between 1500mg – 3000mg a day to maintain phosphate levels less than 6.0 mg/dl. The total daily dose should be divided and taken with meals.  
Note: in studies, doses up to 3750mg were evaluated.

**Duration of Therapy:** Indefinite

**Criteria for Use:** *(bullet points below are all inclusive unless otherwise note)*

- Clinically diagnosed hyperphosphatemia due to renal failure.
  - Failed / intolerant to calcium based binding agent (Tums, Os-Cal, Caltrate, Phoslo)
- Or
- Failed/ intolerant to Rocaltrol
- Or
- Failed intolerant to aluminum based binding agents (AlternaGel, Alu-tabs, Amphojel)
- and
- Failed/ intolerant to Renagel

**Cautions:**

The following conditions were not included in Fosrenol clinical studies.

- Acute peptic ulcer disease
- Ulcerative colitis
- Crohn's disease
- Bowel obstruction

**Contraindications:**

- None known

**Not Approved if:**

- The above criteria is not met.

P&T Approval: \_\_\_\_\_ Date: \_\_\_\_\_